zantac 150 mg/10ml syrup
ltt pharma limited - ranitidine hydrochloride - syrup - 150 mg/10ml - h2-receptor antagonists
zantac 300 mg film coated tablet
ltt pharma limited - ranitidine hydrochloride - film coated tablet - 300 mg - h2-receptor antagonists
zantac 150 mg film coated tablet
ltt pharma limited - ranitidine hydrochloride - film coated tablet - 150 mg - h2-receptor antagonists
zantac ranitidine 300mg (as hydrochloride) effervescent tablet (new formulation)
aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, effervescent - excipient ingredients: povidone; sodium bicarbonate; aspartame; sodium benzoate; monosodium dihydrogen citrate; flavour - 1. short-term treatment of provenduodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ucler. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesophagitis. the intravenous injection is indicated where oral treatment is inappropriate.
zantac ranitidine 300mg (as hydrochloride) effervescent tablet (new formulation)
aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, effervescent - excipient ingredients: aspartame; sodium bicarbonate; monosodium dihydrogen citrate; povidone; sodium benzoate; flavour - 1. short-term treatment of provenduodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ucler. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesophagitis. the intravenous injection is indicated where oral treatment is inappropriate.
zantac ranitidine 150mg (as hydrochloride) effervescent tablet
aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, effervescent - excipient ingredients: sodium bicarbonate; sodium benzoate; aspartame; monosodium dihydrogen citrate; povidone; flavour - short term treatment of proven duodenal and gastric ulcer. maintenance treatment to reduce the risk of relapse in duodenal ulcer. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. treatment of gastrinoma (zollinger-ellison syndrome). short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. treatment of scleroderma oesophagitis. indications as at 2 november 1993: 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesopha
zantac 150mg dispersible tablets
aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, dispersible - excipient ingredients: magnesium stearate; croscarmellose sodium; microcrystalline cellulose; hyprolose; titanium dioxide; saccharin sodium; hypromellose; flavour - 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesphagitis. the intravenous injection is indicated where oral treatment is inappropriate
zantac-ranitidine 150 tablet
pharmacare limited û woodmead - tablet - see ingredients - each tablet contains ranitidine hydrochloride equivalent to 150 mg ranitidine
zantac-ranitidine 300 tablet
pharmacare limited û woodmead - tablet - see ingredients - each tablet contains ranitidine hydrochloride 336,0 mg equivalent to 300 mg ranitidine
zantac injection 25 mgml
glaxo smith kline (israel) ltd - ranitidine as hydrochloride - solution for injection - ranitidine as hydrochloride 25 mg/ml - ranitidine - ranitidine - adults:zantac injection is indicated for the treatment of duodenal ulcer, benign gastric ulcer, post - operative ulcer, reflux oesophagitis, zollinger - ellison syndrome and the following conditions where reduction of gastric secretion and acid output is desirable.the prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patients and before general anaesthesia in patients considered to be at risk of acid aspiration (mendelson’s syndrome), particularly obstetric patients during labour. children (6 months to 18 years):zantac injection is indicated for the short term treatment of peptic ulcer and the treatment of gastro-oesophageal reflux, including reflux oesophagitis and symptomatic relief of gastro-oesophageal reflux disease.